2,550 results on '"Wechalekar A"'
Search Results
2. Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker
Catalog
Books, media, physical & digital resources
3. Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features
4. The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study
5. Prognostic value of multimodality imaging in the contemporary management of cardiac sarcoidosis
6. Amyloid Light Chain (AL) Amyloidosis
7. Treatment of Amyloid Light-Chain Amyloidosis
8. Variability in the distance between the suprascapular notch with the spine of the scapulae and the acromion
9. Abstract 4144740: Characteristics and Natural History of Early ATTR Cardiac Amyloid Infiltration
10. Editorial: Synovial pathobiology and pathogenesis of inflammatory arthritis, volume II
11. Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations
12. Extensive cardiac FDG uptake in a patient with AL amyloidosis
13. Ascertaining the prognostic role of cardiac resynchronisation therapy in cardiac sarcoidosis: A comparison with ischaemic cardiomyopathy
14. Motion correction for diagnosis of cardiac sarcoidosis—do we have all the answers?
15. A rare case of extensive biventricular cardiac sarcoidosis with reversible torrential tricuspid regurgitation
16. Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
17. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
18. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort
19. Comparing outcomes of an ‘early’ versus ‘late’ diagnosis of cardiac sarcoidosis following a baseline presentation of high-grade atrioventricular block
20. Ethnic diversity in presentation and outcome of Waldenström macroglobulinemia and IgM monoclonal gammopathy of clinical significance in the United Kingdom
21. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748
22. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
23. Characterisation and management of expected and unexpected urgent findings from positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in cardiovascular disease
24. Role of serial 18F-fludeoxyglucose positron emission tomography in determining the therapeutic efficacy of immunosuppression and clinical outcome in patients with cardiac sarcoidosis
25. Racial disparities among patients with cardiac sarcoidosis and arrhythmias in the United States: A propensity matched-analysis from the national inpatient sample database 2016-2020
26. Treatment of AL Amyloidosis
27. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort
28. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
29. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
30. Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis
31. Cardiovascular Magnetic Resonance (CMR) in Transthyretin Amyloid Cardiomyopathy – a Study of Natural History of Treatment Response
32. Cardiac Magnetic Resonance (CMR) and 18F-FDG Positron Emission Tomography (PET) Imaging in Suspected Immune Checkpoint Inhibitor (ICI)-associated Myocarditis
33. Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients
34. Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment
35. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
36. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
37. Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis
38. Immune checkpoints in rheumatoid arthritis: progress and promise
39. Transcriptomic profiling of programmed cell death 1 (PD-1) expressing T cells in early rheumatoid arthritis identifies a decreased CD4 + PD-1 + signature post-treatment
40. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
41. Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure
42. Normative Values for Pinch Strength—Relationship With Joint Hypermobility as Measured With the Beighton Criteria
43. Primary Light Chain (AL) Amyloidosis
44. Abstract 11740: Redefining Cardiac Involvement in Systemic Immunoglobulin Light Chain Amyloidosis and Treatment Implications
45. Abstract 11617: Characterisation of Blood Biomarkers in Cardiac ATTR Amyloidosis
46. Artificial intelligence and the future of radiographic scoring in rheumatoid arthritis: a viewpoint
47. S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
48. P910: DISPARATE PREDICTION OF OUTCOMES IN A UNIFORMLY TREATED COHORT OF PATIENTS WITH AL AMYLOIDOSIS STRATIFIED BY MAYO 2012 AND EUROPEAN CARDIAC STAGING SYSTEMS
49. PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
50. PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.